Effective treatment of
allergic diseases
such as asthma and atopic dermatitis

Airsonett AB announced today that the company had signed an agreement with the region of Halland in Sweden. The agreement is for the treatment of patients with severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with the company’s patented technology Temperature-controlled Laminar Airflow (TLA).

Airsonett announced today that the company has signed an agreement with the region of Kalmar for the treatment of patients with severe allergic asthma. The agreement is the third of its kind for Airsonett in Sweden this year, for prescription of the company’s unique treatment; Temperature controlled Laminar Airflow (TLA).

Region Västra Götaland is the latest in a line of Swedish regions to sign an agreement with Airsonett for TLA treatment. The regions Stockholm and Östergötland have previously signed similar…

The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who,…

The new app Allergy Diary has been developed for IOS and Android in collaboration between MACVIA-LR and ARIAR, a European network for monitoring allergy. The app is an important tool…

National health care in the South Swedish region of Skåne has updated its guidelines for treatment of patients with severe allergic asthma. Airsonett and the treatment with the TLA technology…

A re-analysis of time to onset (TTO) from a previously published study by Boyle et al, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of…

Presentation of new AIR-4 study at European Respiratory Society congress in Paris Sep 16, 2018  An independent study by Professor C. Wang concludes in the study title “A nocturnal temperature…